AI-measured pancreatic volume decline may enrich pancreatic cancer risk prediction

Patients later developing pancreatic cancer lost more pancreatic volume over 5 years (9.71 vs 1.23 mL; p=0.013). Adding this marker to a basic model raised AUC from 0.679 to 0.823. Validation is needed before clinical use.

• In a retrospective case-control study of 40 PDAC patients and 61 controls with ≥5 years pre-diagnostic CT, AI-measured pancreatic volume declined faster in those who later developed cancer.
• Including the volume change marker in a covariate model improved AUC from 0.679 to 0.823.
• Exploratory tissue transcriptomic profiling adjacent to non-invasive and invasive PDAC found concordantly altered genes, but no within-patient imaging-transcriptomic correlation was performed.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.